NanoRepro AG (NN6):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:NanoRepro AG (NN6) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8078
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NanoRepro AG (NanoRepro) is a manufacturer of fast-diagnostics and nutritional food supplements for home and clinical use. The company offers wide range of rapid diagnostic tests products in the areas of family planning, disease detection (preventive healthcare), food intolerances, allergies and infectious diseases. Its products portfolio includes ovuquick, graviquick, glutencheck, cholesterincheck, fertiquick, vagiquick, menoquick, graviquick fruhtest, fobcheck, heli-c-check, alkoholtest, milkcheck, allergocheck, and eiercheck. The company works in partnership with companies and institutions including University of Marburg, Research Center for Medical Engineering and Biotechnology, Bad Langensalza, Germany. Dedicare AB, Hartmann USA, Inc., Farmaceutica Remedia SA, and others. The Company markets its products through a network of distributors worldwide. NanoRepro is headquartered in Marburg, Germany.

NanoRepro AG (NN6) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NanoRepro AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
NanoRepro AG, Medical Devices Deals, 2012 to YTD 2018 9
NanoRepro AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NanoRepro AG, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
NanoRepro Acquires Alphabiol Brand from Alphablom 11
Equity Offering 12
Nanorepro Raises USD0.6 Million in Rights Offering of Shares 12
NanoRepro Raises USD1 Million in Rights Offering of Shares 13
NanoRepro to Raise Funds through Public Offering of Shares 14
NanoRepro Raises USD1.7 Million in Rights Offering of Shares 15
NanoRepro Raises USD1.1 Million in Rights Offering of Shares 16
NanoRepro AG – Key Competitors 17
NanoRepro AG – Key Employees 18
NanoRepro AG – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Apr 25, 2018: NanoRepro Increases Sales and Achieves Positive Operating Result (EBITDA) 20
Dec 05, 2017: NanoRepro With Higher Sales and Better Results 21
Aug 03, 2017: NanoRepro Increases Growth in the Second Quarter 22
Apr 25, 2017: NanoRepro: Sales Grow in the First Quarter 23
Apr 21, 2017: NanoRepro: Company Expects Revenue to Increase by at Least 30% in 2017 24
Jan 25, 2017: NanoRepro Announces Preliminary Figures for the 2016 Financial Year 25
Other Significant Developments 26
Apr 10, 2018: NanoRepro Reaches Its Annual Targets and Wants to Grow Strongly in 2018 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
NanoRepro AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NanoRepro AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NanoRepro AG, Deals By Therapy Area, 2012 to YTD 2018 8
NanoRepro AG, Medical Devices Deals, 2012 to YTD 2018 9
NanoRepro AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NanoRepro Acquires Alphabiol Brand from Alphablom 11
Nanorepro Raises USD0.6 Million in Rights Offering of Shares 12
NanoRepro Raises USD1 Million in Rights Offering of Shares 13
NanoRepro to Raise Funds through Public Offering of Shares 14
NanoRepro Raises USD1.7 Million in Rights Offering of Shares 15
NanoRepro Raises USD1.1 Million in Rights Offering of Shares 16
NanoRepro AG, Key Competitors 17
NanoRepro AG, Key Employees 18

List of Figures
NanoRepro AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
NanoRepro AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
NanoRepro AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
NanoRepro AG, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[NanoRepro AG (NN6):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lancaster Colony Corporation:企業の戦略・SWOT・財務情報
    Lancaster Colony Corporation - Strategy, SWOT and Corporate Finance Report Summary Lancaster Colony Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Aston Martin Lagonda Global Holdings plc (AML):企業の財務・戦略的SWOT分析
    Aston Martin Lagonda Global Holdings plc (AML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Universal Robina Corp:企業の戦略・SWOT・財務情報
    Universal Robina Corp - Strategy, SWOT and Corporate Finance Report Summary Universal Robina Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Australian Securities & Investments Commission:企業の戦略的SWOT分析
    Australian Securities & Investments Commission - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Telormedix SA-製薬・医療分野:企業M&A・提携分析
    Summary Telormedix SA (Telormedix) is a biopharmaceutical company. The company develops and provides immune drugs for the treatment of cancer and other infectious diseases. It offers products such as TMX-201, TMX-202 and vesimune (TMX-101). Its vesimune (TMX-101) provides treatment for superficial b …
  • CGN Power Co Ltd (1816):電力:M&Aディール及び事業提携情報
    Summary CGN Power Co Ltd (CGN Power) a subsidiary of China General Nuclear Power Corp, is an electric utility. It generates and sells nuclear power and provides services. The company produces electricity using nuclear source. Under electricity sales contracts, CGN Power sells energy. It also has int …
  • General Motors Co (GM):企業の財務・戦略的SWOT分析
    General Motors Co (GM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Nanomerics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Nanomerics Ltd (Nanomerics) is a healthcare solution provider that develops drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides. The company offers products such as METDoloron, METSporine, METAmphizon, METEnkalon, MET undisclosed, MET ocular undiscl, ocular und …
  • SpectraCure AB:製薬・医療:M&Aディール及び事業提携情報
    Summary SpectraCure AB (SpectraCure) is a provider of cancer treatment solutions that offers medical device systems containing laser light sources and photoreactive drugs. The company develops and therapy system, commercializes photodynamic with IDOSE for tumors. It provides IDOSE platform which all …
  • Kobayashi Pharmaceutical Co Ltd (4967)-製薬・医療分野:企業M&A・提携分析
    Summary Kobayashi Pharmaceutical Co Ltd (Kobayashi) is a manufacturer and distributor of pharmaceutical, health and personal care products. The company offers OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, cooling gel sheets, sanitary products, household sundries, and body w …
  • Dian Diagnostics Group Co Ltd (300244):製薬・医療:M&Aディール及び事業提携情報
    Summary Dian Diagnostics Group Co Ltd (Dian Diagnostics) is a medical diagnostic service provider. The company provides forensic authentication services, commercialization of diagnostic products, research and development in medical diagnostics and contract research services. It offers solutions in s …
  • Imprimis Pharmaceuticals Inc (IMMY):製薬・医療:M&Aディール及び事業提携情報
    Summary Imprimis Pharmaceuticals Inc (Imprimis), formerly Transdel Pharmaceuticals Inc., focuses on the development and commercialization of proprietary drug formulations in the therapeutic areas of urology and ophthalmology. The company by utilizing its SSP Technology develops injectable Dropless T …
  • Johnson Service Group plc (JSG):企業の財務・戦略的SWOT分析
    Summary Johnson Service Group plc (JSG) is a business and consumer service provider that provides textile services. The company provides dry cleaning and textile rental services. It offers dry cleaning services such as commercial dry cleaning, specialist textile consulting, garment aftercare service …
  • Abercrombie & Fitch Co:企業の戦略・SWOT・財務分析
    Abercrombie & Fitch Co - Strategy, SWOT and Corporate Finance Report Summary Abercrombie & Fitch Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • JBCC Holdings Inc (9889):企業の財務・戦略的SWOT分析
    JBCC Holdings Inc (9889) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nisshin Seifun Group Inc:企業の戦略・SWOT・財務分析
    Nisshin Seifun Group Inc - Strategy, SWOT and Corporate Finance Report Summary Nisshin Seifun Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Zimmer Biomet Holdings Inc (ZBH)-医療機器分野:企業M&A・提携分析
    Summary Zimmer Biomet Holdings Inc (Zimmer Biomet) is a medical device company with focus on musculoskeletal healthcare. It carries out the design, development, manufacture, and marketing of reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, cr …
  • Magnitogorsk Metallurgicheskiy Kombinat:企業の戦略・SWOT・財務情報
    Magnitogorsk Metallurgicheskiy Kombinat - Strategy, SWOT and Corporate Finance Report Summary Magnitogorsk Metallurgicheskiy Kombinat - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Laboratory Corp of America Holdings (LH)-医療機器分野:企業M&A・提携分析
    Summary Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics la …
  • Valneva SE (VLA):企業の財務・戦略的SWOT分析
    Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆